CS
RLMD icon

Candriam SCA’s Relmada Therapeutics RLMD Stock Holding History

Candriam SCA’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-92,186
Closed -$322K – 920
2022
Q4 		$322K Sell
92,186
-82,419
-47% -$724K ﹤0.01% 836
2022
Q3 		$6.46M Buy
174,605
+32,419
+23% +$898K 0.05% 342
2022
Q2 		$2.7M Buy
142,186
+6,510
+5% +$142K 0.02% 436
2022
Q1 		$3.66M Buy
+135,676
New +$2.81M 0.02% 409

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's RLMD Position: Q1 2023 in Review

Candriam SCA sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 92,186 shares — an estimated $322K sold.

Candriam SCA first reported a position in RLMD in Q1 2022 and held it in 4 quarters. The position peaked at $6.46M in Q3 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • Candriam SCA reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Candriam SCA sold 92,186 Relmada Therapeutics shares in Q1 2023, an estimated $322K.
  • Candriam SCA first reported a position in Relmada Therapeutics in Q1 2022 and held it in 4 quarters.
  • Candriam SCA's Relmada Therapeutics position peaked at $6.46M in Q3 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.